Skip to content
AnimalSynergistic healing and recovery peptide blend

BPC-157 + TB-500 Blend (10mg + 10mg)

Also indexed as BPC/TB Blend, Healing Stack, BPC 10mg TB 10mg Combo, Recovery Blend

BPC-157 + TB-500 is a pre-mixed peptide blend combining Body Protection Compound-157 (a gastric pentadecapeptide) and Thymosin Beta-4 fragment (TB-500) into a single vial for convenience. Together, these two peptides target overlapping and complementary pathways in tissue repair, angiogenesis, and inflammation modulation. The combination is widely used in the research and biohacking communities for accelerated musculoskeletal recovery, tendon and ligament healing, and systemic anti-inflammatory effects.

Overview

Following subcutaneous or intramuscular administration, BPC-157 demonstrates remarkable stability against enzymatic degradation in gastric juice and plasma — a property that distinguishes it from most peptides of similar size. TB-500's synthetic active fragment distributes systemically and has been detected in tissue remodeling contexts including cardiac, musculoskeletal, and dermal repair in rodent models. The combination exploits the local repair optimization of BPC-157 with the systemic homing properties of TB-500's actin-sequestering mechanism, potentially achieving tissue healing outcomes superior to either agent alone at equivalent doses.

Proposed mechanism

BPC-157 upregulates growth hormone receptor expression, promotes nitric oxide synthesis via the eNOS pathway, and stimulates VEGF-driven angiogenesis to accelerate tissue vascularization and repair. TB-500 (a synthetic analogue of the Thymosin Beta-4 protein's active region, Ac-SDKP) sequesters G-actin, promotes cell migration and differentiation, and independently activates angiogenic and anti-inflammatory cascades. Together they act synergistically: BPC-157 anchors local tissue repair and gut-brain axis modulation while TB-500 drives systemic cellular migration and cytoskeletal remodeling, producing complementary and potentially additive healing outcomes.

What the evidence supports

Most data comes from preclinical animal studies. Human clinical trial evidence is limited or absent.

Graded Animal

Evidence drawn from in vivo animal models or in vitro systems. Mechanistically informative; translation to humans is unproven.

Key citations

Representative primary sources, including results that did not favour the compound.

  1. [1]

    Stable gastric pentadecapeptide BPC 157: novel therapy in gastrointestinal tract

    · Current Pharmaceutical Design, Sikiric et al. · 2006

  2. [2]

    BPC 157 and tendon healing: tendon fibroblast migration and proliferation

    · Journal of Physiology and Pharmacology · 2015

  3. [3]

    Thymosin Beta-4 and Ac-SDKP: actin sequestration and angiogenesis

    · Annals of the New York Academy of Sciences, Vol. 1112 · 2007

  4. [4]

    Thymosin beta4 activates integrin-linked kinase and promotes cardiac cell migration, survival and cardiac repair

    · Nature, 432:466–472 · 2004

  5. [5]

    BPC 157 and the vascular healing: VEGF upregulation and eNOS pathway

    · Current Medicinal Chemistry, related Sikiric group publications · 2016

Citation records in this build are illustrative placeholders for the design.

Reference information for research purposes. Not medical advice, and not a recommendation to use any compound. Many entries describe substances that are not approved for human use.

Related profiles

Adamax

Anecdotal

Nootropic peptide blend for cognition and mood

Adamax is a research peptide blend reported to combine nootropic and neuroprotective peptide components aimed at enhancing cognitive function, mood stability, and neural recovery. It is marketed primarily for its potential effects on dopaminergic and serotonergic signaling pathways. Evidence is largely limited to preclinical and anecdotal sources, with no published human clinical trials specific to the Adamax formulation.

0 RCT · 0 human · 0 preclinical

cognition

AHK-Cu

Human-limited

Copper peptide for skin regeneration and repair

AHK-Cu is a copper-binding tripeptide (Ala-His-Lys) complexed with copper(II) ions, closely related to the well-studied GHK-Cu peptide. It stimulates collagen and glycosaminoglycan synthesis in skin fibroblasts while exerting antioxidant and anti-inflammatory activity. Primarily researched in the context of skin regeneration, wound healing, and hair follicle stimulation.

0 RCT · 0 human · 0 preclinical

skin

B7-33

Animal

Biased RXFP1 agonist for cardiac fibrosis

B7-33 is a single-chain peptide analog of human relaxin-2, engineered to selectively activate the RXFP1 receptor without triggering the cAMP signaling pathway. It demonstrates potent anti-fibrotic, vasodilatory, and cardioprotective effects in preclinical models. Research primarily focuses on its potential in heart failure, pulmonary arterial hypertension, and organ fibrosis.

0 RCT · 0 human · 0 preclinical

Cardiovascular